메뉴 건너뛰기




Volumn 45, Issue 1-3, 2001, Pages 53-56

Proof of efficacy trials: Endpoints

Author keywords

Antiepileptic drugs; Endpoints; Proof of efficacy trials; Response ratio; Seizure frequency

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE;

EID: 0034913378     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(01)00216-9     Document Type: Conference Paper
Times cited : (25)

References (10)
  • 2
    • 0035115781 scopus 로고    scopus 로고
    • Quantitative assessment of seizure severity for clinical trials: A review of approaches to seizure components
    • (2001) Epilepsia , vol.42 , pp. 119-129
    • Cramer, J.A.1    French, J.A.2
  • 6
    • 0004502140 scopus 로고    scopus 로고
    • Personal communication, Pfizer Global Research and Development, Pfizer Inc.
    • (2000)
    • Kugler, A.R.1
  • 7
    • 0027712633 scopus 로고
    • Handling seizure data: Special problems
    • French, J.A., Dichter, M.A., Leppik, I.E. (Eds.), New Antiepileptic Drug Development: Preclinical and Clinical Aspects. Elsevier, Amsterdam
    • (1993) Epilepsy Res. Suppl. , vol.10 , pp. 175-178
    • Pierce, M.W.1    Shuh, V.S.2
  • 8
    • 0027769096 scopus 로고
    • Alternative analyses for antiepileptic drug trials
    • French, J.A., Dichter, M.A., Leppik, I.E. (Eds.), New Antiepileptic Drug Development: Preclinical and Clinical Aspects. Elsevier, Amsterdam
    • (1993) Epilepsy Res. Suppl. , vol.10 , pp. 167-174
    • Pledger, G.W.1    Sahlroot, J.T.2
  • 10
    • 0027374164 scopus 로고
    • Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind placebo-controlled parallel-group study
    • (1993) Neurology , vol.43 , pp. 2292-2298


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.